[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alaunos Therapeutics Inc (TCRT)

Alaunos Therapeutics Inc (TCRT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 46,890
  • Shares Outstanding, K 24,422
  • Annual Sales, $ 10 K
  • Annual Income, $ -4,180 K
  • EBIT $ -4 M
  • EBITDA $ -4 M
  • 60-Month Beta -1.02
  • Price/Sales 9,524.58
  • Price/Cash Flow N/A
  • Price/Book 3.60

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.8100 +7.18%
on 07/24/26
2.4800 -21.77%
on 06/29/26
-0.2100 (-9.77%)
since 06/24/26
3-Month
1.8100 +7.18%
on 07/24/26
3.0900 -37.22%
on 05/28/26
-0.8200 (-29.71%)
since 04/24/26
52-Week
1.6700 +16.17%
on 08/22/25
4.5900 -57.73%
on 10/09/25
-1.0372 (-34.84%)
since 07/24/25

Most Recent Stories

More News
Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study

This statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this model Liver-weight...

TCRT : 1.9400 (+1.04%)
Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and...

TCRT : 1.9400 (+1.04%)
Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT)  today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating...

TCRT : 1.9400 (+1.04%)
Ziopharm: Q1 Earnings Snapshot

Ziopharm: Q1 Earnings Snapshot

TCRT : 1.9400 (+1.04%)
Valion Bio Appoints Melinda Lackey as General Counsel

Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership Team

TCRT : 1.9400 (+1.04%)
VBIO : 0.2970 (+3.85%)
Ziopharm: Q4 Earnings Snapshot

Ziopharm: Q4 Earnings Snapshot

TCRT : 1.9400 (+1.04%)
Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model ALN1003 also demonstrated reductions in liver weight and improvements...

TCRT : 1.9400 (+1.04%)
Ziopharm: Q3 Earnings Snapshot

Ziopharm: Q3 Earnings Snapshot

TCRT : 1.9400 (+1.04%)
Ziopharm: Q2 Earnings Snapshot

Ziopharm: Q2 Earnings Snapshot

TCRT : 1.9400 (+1.04%)
Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

TCRT : 1.9400 (+1.04%)

Business Summary

Alaunos Therapeutics Inc. is a clinical-stage oncology-focused cell therapy company. It focused on developing T-cell receptor therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform. Alaunos Therapeutics Inc., formerly known as Ziopharm Oncology Inc., is based in HOUSTON....

See More

Key Turning Points

3rd Resistance Point 2.1810
2nd Resistance Point 2.0808
1st Resistance Point 2.0104
Last Price 1.9400
1st Support Level 1.8398
2nd Support Level 1.7396
3rd Support Level 1.6692

See More

52-Week High 4.5900
Fibonacci 61.8% 3.4746
Fibonacci 50% 3.1300
Fibonacci 38.2% 2.7854
Last Price 1.9400
52-Week Low 1.6700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.